Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imprime PGG with cetuximab, paclitaxel, and carboplatin in first-line advanced NSCLC
2008-006778-14Phase 2Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of odetiglucan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Primary antitumor activity endpoint and Primary safety endpoint. Started Dec 2008; status: completed.
02
Drugs
odetiglucan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-006778-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006778-14.